FDA outlines pathway for approval of personalized gene-editing therapies

The U.S. Food and Drug Administration released a set of recommendations describing how developers can pursue regulatory approval for gene-editing treatments that are customized to a single patient’s genetic mutation.

The guidance outlines a step-by-step framework, including requirements for pre-clinical data, manufacturing controls, and clinical trial design that reflect the personalized nature of the therapy.

FDA officials said the pathway is intended to provide clarity while maintaining safety standards, and it is part of an ongoing effort to adapt the regulatory system to emerging genome-editing technologies.